Daiichi Sankyo: Carcinoma, Non-Small-Cell Lung trials

The registry lists 35 Carcinoma, Non-Small-Cell Lung studies with Daiichi Sankyo as lead sponsor. 5 are open to participants now and 15 have results posted.

Phase 1 14Phase 2 13Phase 3 7No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingNCT07890714Phase 1/2
• A Study of DS-3939a in Participants With Solid TumorsNot yet recruitingNCT07739966Phase 1/2
• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Phase 3
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)RecruitingNCT06809764
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 2
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active, not recruitingNCT04656652Phase 3Results posted
• Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT04644237Phase 2Results posted
• Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)CompletedNCT04484142Phase 2Results posted
• DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03599518Phase 1Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerTerminatedNCT03505710Phase 2Results posted
• DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03255083Phase 1Results posted
• Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)TerminatedNCT02134015Phase 3Results posted
• A Study of DS-2248 in Participants With Advanced Solid TumorsTerminatedNCT01288430Phase 1Results posted
• Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerTerminatedNCT01244191Phase 3Results posted
• Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT01211483Phase 1/2Results posted
• CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT01199068Phase 1Results posted
• CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT01199055Phase 1Results posted
• Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT01101334Phase 2Results posted
• Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung CancerCompletedNCT00806286Phase 2Results posted
• Taxoprexin Plus Carboplatin Treatment for Advanced Lung CancerCompletedNCT00243867Phase 3Results posted
• A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT06644768Phase 1/2
• A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line TreatmentsCompletedNCT06617390
• Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of TreatmentCompletedNCT06557967
• Medical Access Program for Patritumab DeruxtecanNo longer availableNCT06099639
• A Study of Prevalence of HER3 Expression in Non-Small Cell Lung CancerCompletedNCT05769764
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active, not recruitingNCT05555732Phase 3
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05215340Phase 3
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingNCT04676477Phase 1
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingNCT04526691Phase 1
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1
• First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Active, not recruitingNCT03401385Phase 1
• U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerActive, not recruitingNCT03260491Phase 1
• CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)CompletedNCT00991796Phase 2
• Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00061854Phase 2
• DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00005091Phase 2